Finland· FI-REL-REL63069
ROMVIMZA
A vimseltinib product containing vimseltinib, registered in Finland by Deciphera Pharmaceuticals (Netherlands) B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Vimseltinib is registered in 10 of 19 countries.
Countries holding a registration under ATC L01EX29 (vimseltinib), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Vimseltinib · ATC L01EX29
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Spainprice
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Vimseltinib
- Manufacturer
- Deciphera Pharmaceuticals (Netherlands) B.V.
- Country
- Finland (FI)
- ATC code
- L01EX29
- ATC class
- Vimseltinib
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vimseltinib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesROMVIMZADeciphera Pharmaceuticals, LLC
- CzechiaROMVIMZADeciphera Pharmaceuticals (Netherlands) B.V., Amsterdam
- SpainROMVIMZA 30 MG CAPSULAS DURASDeciphera Pharmaceuticals (Netherlands) B.V.
- FranceROMVIMZA 30 mg, géluleDECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS)
- IrelandROMVIMZA 30 mg hard capsulesDeciphera Pharmaceuticals (Netherlands) B.V.
- BelgiumRomvimza 30 mgDeciphera Pharmaceuticals (Netherlands)
- NetherlandsROMVIMZA 30 mg harde capsulesDeciphera Pharmaceuticals (Netherlands) B.V.
- PolandRomvimzaDeciphera Pharmaceuticals (Netherlands) B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Romvimza
- Liechtenstein · Romvimza
- Norway · Romvimza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dd98084c-67f9-4940-8ab9-c41c401aad61 GET /v1/drugs/dd98084c-67f9-4940-8ab9-c41c401aad61?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kapseli, kova",
"route": "Suun kautta",
"ddd_unit": null,
"strength": "30 mg",
"atc_label": "vimseltinibi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/25/1968/003",
"fimea_rel_id": "REL63069",
"authorised_at": "2025-09-17"
}See everything about vimseltinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.